Clinical studies with fluoxetine in obesity

Area of Science:

• Pharmacology
• Metabolic Disorders
• Clinical Trials

Background:

• Selective serotonin reuptake inhibitors (SSRIs) are primarily known for their psychiatric applications.
• Obesity and type 2 diabetes are significant global health concerns requiring effective therapeutic interventions.
• Understanding the metabolic effects of SSRIs beyond their neurological impact is crucial for comprehensive patient care.

Purpose of the Study:

• To evaluate the efficacy of fluoxetine in promoting weight loss in obese individuals.
• To assess the impact of fluoxetine on glycemic control in obese diabetic patients.
• To analyze the safety and tolerability profile of fluoxetine in long-term obesity treatment.

Main Methods:

• Systematic review of six double-blind, placebo-controlled studies.
• Analysis of weight changes in patients receiving fluoxetine (60 mg daily) versus placebo.
• Safety analysis of data from 3491 obese patients in controlled clinical trials up to 52 weeks.

Main Results:

• Fluoxetine treatment resulted in consistent and significant weight loss, approximately 0.5 kg/wk, peaking at 12-20 weeks.
• Obese diabetic patients showed improvements in glycemic control indices alongside weight reduction.
• Common adverse events (headache, nausea, insomnia) were reported more frequently in the fluoxetine group but were generally manageable.

Conclusions:

• Fluoxetine is an effective treatment for obesity, inducing substantial weight loss.
• The medication demonstrates benefits for glycemic control in obese diabetic populations.
• Fluoxetine is well-tolerated and safe for the management of obesity and associated metabolic complications.